Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:30 PM ET.
Management led by President and CEO Rich Daly will webcast the presentation; the webcast is available via the company investor website and a replay will be accessible for at least 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CPRX was down 0.78% while momentum-screened peers like IBRX and TARS showed upside moves, indicating today’s setup looks more stock-specific than part of a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings timing update | Neutral | -1.4% | Announced dates for Q4 and full-year 2025 results release and call. |
| Jan 05 | Advocacy summit | Neutral | -1.5% | Launched week-long Catalyst Advocacy Scholars Summit with Notre Dame. |
| Dec 15 | JP Morgan conference | Neutral | +2.4% | Planned presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 24 | BofA CNS conference | Neutral | +1.0% | Participation in Bank of America CNS Therapeutics Virtual Conference. |
| Nov 19 | Growth recognition | Positive | -0.7% | Named to Deloitte Technology Fast 500™ for <b>249%</b> revenue growth 2021–2024. |
Recent non-fundamental news (conferences, recognition, programs) has produced modest single-day moves in both directions, suggesting limited but noticeable sensitivity to visibility events.
Over the past several months, Catalyst has focused on visibility and recognition events. It announced an upcoming Q4 and full-year 2025 results release with a -1.4% next-day move, hosted the CASS advocacy summit with a -1.51% move, and participated in multiple conferences (J.P. Morgan, Bank of America CNS) with modest positive reactions of 2.37% and 0.99%. Recognition on Deloitte’s Technology Fast 500™, tied to 249% revenue growth from 2021–2024, saw a small -0.66% move. Today’s Barclays conference appearance fits this pattern of investor-relations and profile-building updates.
Market Pulse Summary
This announcement highlights Catalyst’s participation at the Barclays healthcare conference on March 10, 2026, with a webcast and 30-day replay, reinforcing its ongoing investor-relations efforts. Recent history shows similar conference and recognition updates produced modest single-day moves, while broader fundamentals, such as the previously reported 249% revenue growth from 2021–2024, underpin the story. Investors may watch the approaching Q4 and full-year 2025 results date for more substantive financial information.
AI-generated analysis. Not financial advice.
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, being held in Miami, Florida.
Presentation Details
Date: Tuesday, March 10, 2026
Presentation: 3:30 PM ET
Webcast Link
The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Contact information: Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC (646) 249-6817 Ignacio.Guerrero-Ros@russopartnersllc.com
FAQ
When will Catalyst Pharmaceuticals (CPRX) present at the Barclays 28th Annual Global Healthcare Conference?
Who from Catalyst Pharmaceuticals (CPRX) will participate in the March 10, 2026 Barclays conference presentation?
How can investors watch Catalyst Pharmaceuticals (CPRX) presentation on March 10, 2026?
Will Catalyst Pharmaceuticals (CPRX) provide a replay of its Barclays conference presentation and for how long?
What topics will Catalyst Pharmaceuticals (CPRX) management likely cover at the March 10, 2026 Barclays conference?
